$656 Million is the total value of Bellevue Asset Management AG's 127 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | Biogen Inc. | $25,743,000 | +22.9% | 84,030 | +17.1% | 3.92% | +14.8% |
| AMGN | Buy | Amgen Inc. | $19,967,000 | +20.3% | 123,000 | +2.5% | 3.04% | +12.4% |
| ILMN | Buy | Illumina, Inc. | $17,549,000 | +13.9% | 91,425 | +4.3% | 2.67% | +6.4% |
| MYL | Buy | Mylan Inc. | $17,048,000 | +88.2% | 315,300 | +40.1% | 2.60% | +75.8% |
| BDX | Buy | Becton, Dickinson and Company | $16,191,000 | +32.2% | 105,075 | +13.8% | 2.47% | +23.5% |
| CAH | Buy | Cardinal Health, Inc. | $15,308,000 | +149.1% | 171,480 | +114.4% | 2.33% | +132.7% |
| TEVA | Buy | Teva Pharmaceuticals, Inc.adr | $11,600,000 | +21.4% | 176,720 | +4.4% | 1.77% | +13.4% |
| ENDP | Buy | Endo International PLC | $10,469,000 | -4.4% | 171,000 | +8.2% | 1.60% | -10.6% |
| CVS | Buy | CVS Health Corporation | $9,405,000 | +77.3% | 96,200 | +74.9% | 1.43% | +65.7% |
| INCY | Buy | Incyte Corporation | $8,568,000 | +0.9% | 79,000 | +2.6% | 1.30% | -5.8% |
| IONS | New | Ionis Pharmaceuticals Inc. | $8,546,000 | – | 138,000 | +100.0% | 1.30% | – |
| MCK | Buy | McKesson Corporation | $8,481,000 | +11.8% | 43,000 | +4.9% | 1.29% | +4.4% |
| BSX | Buy | Boston Scientific Corporation | $8,482,000 | +29.2% | 460,000 | +15.0% | 1.29% | +20.6% |
| JAZZ | Buy | Jazz Pharmaceuticals Public Limited Company | $8,434,000 | +13.4% | 60,000 | +7.1% | 1.28% | +5.9% |
| CNC | Buy | Centene Corporation | $6,952,000 | +540.7% | 105,630 | +428.2% | 1.06% | +498.3% |
| INSYQ | Buy | Insys Therapeutics, Inc. | $6,642,000 | +11.1% | 232,000 | +10.5% | 1.01% | +3.8% |
| ABC | Buy | AmerisourceBergen Corporation | $6,637,000 | +16.5% | 64,000 | +6.7% | 1.01% | +8.7% |
| PRGO | Buy | Perrigo Company plc | $6,367,000 | +1.2% | 44,000 | +10.0% | 0.97% | -5.5% |
| CHRS | Buy | Coherus BioSciences, Inc | $5,901,000 | +28.0% | 257,000 | +11.7% | 0.90% | +19.5% |
| HALO | Buy | Halozyme Therapeutics, Inc. | $5,511,000 | +66.8% | 318,000 | +29.3% | 0.84% | +55.8% |
| EW | Buy | Edwards Lifesciences Corporation | $5,450,000 | -13.9% | 69,000 | +55.1% | 0.83% | -19.6% |
| HZNP | Buy | Horizon Pharma plc | $5,309,000 | +21.8% | 245,000 | +11.4% | 0.81% | +13.8% |
| ALKS | Buy | Alkermes Public Limited Company | $5,199,000 | +50.2% | 65,500 | +11.0% | 0.79% | +40.2% |
| BCR | Buy | C.R. Bard, Inc. | $5,115,000 | +12.0% | 27,000 | +10.2% | 0.78% | +4.6% |
| XENT | Buy | Intersect Ent, Inc. | $5,063,000 | +8.3% | 225,000 | +12.6% | 0.77% | +1.0% |
| EGBN | New | EAGLE PHARMACEUTICALS INC | $4,877,000 | – | 55,000 | +100.0% | 0.74% | – |
| SUPN | Buy | Supernus Pharmaceuticals, Inc. | $4,771,000 | +6.3% | 355,000 | +10.9% | 0.73% | -0.7% |
| CYH | Buy | Community Health Systems, Inc. | $4,628,000 | -33.3% | 174,440 | +7.5% | 0.70% | -37.7% |
| LCI | New | Lannett Inc. | $4,312,000 | – | 107,480 | +100.0% | 0.66% | – |
| BAX | Buy | Baxter International Inc. | $4,197,000 | +155.4% | 110,000 | +120.0% | 0.64% | +138.4% |
| HCA | Buy | HCA Holdings, Inc. | $4,058,000 | +31.2% | 60,000 | +50.0% | 0.62% | +22.4% |
| CERN | Buy | Cerner Corporation | $3,610,000 | +9.5% | 60,000 | +9.1% | 0.55% | +2.2% |
| PFE | Buy | Pfizer Inc. | $3,551,000 | +33.0% | 110,000 | +29.4% | 0.54% | +24.4% |
| SGEN | Buy | Seattle Genetics, Inc. | $3,052,000 | +64.9% | 68,000 | +41.7% | 0.46% | +54.0% |
| MDVN | Buy | Medivation, Inc. | $3,045,000 | +36.2% | 63,000 | +19.8% | 0.46% | +27.1% |
| QGEN | Buy | Qiagen NV | $2,530,000 | +22.6% | 91,500 | +14.4% | 0.38% | +14.2% |
| RDUS | New | Radius Health Inc. | $2,462,000 | – | 40,000 | +100.0% | 0.38% | – |
| ZLTQ | New | Zeltiq Aesthetics Inc. | $2,140,000 | – | 75,000 | +100.0% | 0.33% | – |
| PRTA | Buy | Prothena Corporation plc | $2,111,000 | +210.4% | 31,000 | +106.7% | 0.32% | +190.1% |
| ICPT | Buy | Intercept Pharmaceuticals, Inc. | $2,016,000 | +39.7% | 13,500 | +55.2% | 0.31% | +30.6% |
| BLUE | Buy | Bluebird Bio, Inc. | $1,862,000 | +6.2% | 29,000 | +41.5% | 0.28% | -0.7% |
| PTCT | New | PTC Therapeutics Inc. | $1,782,000 | – | 55,000 | +100.0% | 0.27% | – |
| WMGI | New | Wright Medical Group Inc. | $1,700,000 | – | 70,309 | +100.0% | 0.26% | – |
| JUNO | Buy | Juno Therapeutics, Inc. | $1,627,000 | +21.1% | 37,000 | +12.1% | 0.25% | +13.2% |
| INFI | Buy | Infinity Pharmaceuticals, Inc. | $1,256,000 | +14.3% | 160,000 | +23.1% | 0.19% | +6.7% |
| RARE | New | Ultragenyx Pharmaceuticals Inc. | $1,122,000 | – | 10,000 | +100.0% | 0.17% | – |
| EXEL | Buy | Exelixis, Inc. | $959,000 | +13.9% | 170,000 | +13.3% | 0.15% | +6.6% |
| BTXWS | New | Biotime Inc.w exp 10/01/2018 | $3,000 | – | 2,294 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biogen Inc. | 4 | Q4 2015 | 4.2% |
| Celgene Corporation | 4 | Q4 2015 | 4.1% |
| Gilead Sciences, Inc. | 4 | Q4 2015 | 4.1% |
| Medtronic, Inc. | 4 | Q4 2015 | 3.7% |
| Abbott Laboratories | 4 | Q4 2015 | 3.3% |
| Regeneron Pharmaceuticals, Inc. | 4 | Q4 2015 | 3.0% |
| Amgen Inc. | 4 | Q4 2015 | 3.0% |
| Illumina, Inc. | 4 | Q4 2015 | 2.7% |
| UnitedHealth Group Incorporated | 4 | Q4 2015 | 2.3% |
| Stryker Corporation | 4 | Q4 2015 | 2.2% |
View Bellevue Asset Management AG's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Auris Medical Holding AG | February 14, 2018 | 2,169,625 | 4.5% |
View Bellevue Asset Management AG's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-02-14 |
| 13F-NT | 2023-11-14 |
| 13F-NT | 2023-08-14 |
| 13F-NT | 2023-05-15 |
| 13F-NT | 2023-02-14 |
| 13F-NT | 2022-11-14 |
| 13F-NT | 2022-08-11 |
| 13F-NT | 2022-05-13 |
| 13F-NT | 2022-02-10 |
| 13F-NT | 2021-11-12 |
View Bellevue Asset Management AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.